Tirzepatide Shows Promise for Weight and Glycemic Control in Type 1 Diabetes

Adults with Type 1 Diabetes (T1D) often face the additional challenge of overweight or obesity, which can complicate glycemic management and increase cardiovascular risk. Current treatment strategies primarily focus on insulin therapy, but adjuncts are needed to address the metabolic comorbidities effectively. This systematic review addresses the critical knowledge gap regarding the efficacy and safety of Tirzepatide as an adjunct to insulin in adults with Type 1 Diabetes and concomitant **overweight or obesity.

The systematic review synthesized findings from multiple studies, consistently reporting that Tirzepatide significantly improved glycemic control and promoted weight reduction in adults with Type 1 Diabetes and overweight or obesity. Across the included trials, HbA1c (a measure of average blood sugar over 2-3 months) reductions ranged from 0.8% to 1.5% from baseline, compared to modest changes of 0.1% to 0.3% in placebo or insulin-only groups. Patients treated with Tirzepatide experienced substantial body weight loss, typically between 7% and 15% of their initial body weight, which was significantly greater than the 1% to 3% observed in control arms (p<0.001). Many studies also noted a reduction in total daily insulin dose by 10% to 25% without increasing hypoglycemia risk, and an improvement in time in range (TIR, the percentage of time blood glucose is within target) by +5% to +10%. The most impactful finding was the consistent demonstration of Tirzepatide's ability to improve both glycemic metrics and body weight without a significant increase in hypoglycemia risk when used as an adjunct to optimized insulin regimens.